吉西他滨联合卡铂治疗91例晚期非小细胞肺癌

目的 研究吉西他滨联合卡铂(铂尔定)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用.方法 经病理组织学或细胞学证实的91例非小细胞肺癌患者给予吉西他滨1250mg/m2静滴,第1,8天,卡铂按浓度/时间曲线下面积(AUC)=5给药,静滴,第1天.21天为一周期.结果 全组CR2例,PR35例,NC30例,PD24例,总有效率为40.6%.其中初治组有效率为46.3%(37/80),有2例CR;复治组有效率为18.2%(2/11),无CR病例,两组差异有显著性(P＜0.05).毒副反应为骨髓抑制(白细胞下降及血小板减少),恶心/呕吐和脱发.结论 吉西他滨联合卡铂治疗晚期非小细胞肺癌近期疗效确切,初治组疗效优于复治组,且毒性可耐受,可作为晚期NSCLC的一线化疗方案.

Gemcitabine and carboplatin combination chemotherapy for 91 cases of advanced non-small-cell lung cancer

Objective To evaluate the efficacy and toxicity of the combination of gemcitabine and carboplatin on advanced non-small-cell lung cancer(NSCLC).Methods Ninty-one patients with locally adyanced or metastatic NSCLC were enrolled into the study.The patients received gemcitabine 1250mg/m2 in drip on day 1,8,carboplatin at an AUC of 5 in drip on day 1.administreted in a 21-day cycle.Results An objective response was obtained in 40.6% of parients(2 complete and 35 partial responses),significant difference existed between the native patients and pretreated patients(46.3% Vs 18.2%,P<0.05).The main toxicities were bone marrow suppression,nausea/vomiting and alopecia.Conclusions The combination of gemcitabine and carboplatin is an effective,well-tolerated scheme in the treatment of advanced NSCLC.The efficacy is higher in the native group than in the pretreated group.The treatment can be use as first-line chemotherapy in advanced NSCLC.